Kiniksa Pharmaceuticals International, plc KNSA
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
ARCALYST is an interleukin-1α ("IL-1α") and interleukin-1β ("IL-1β") cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.
We received FDA approval of ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older in March 2021. Recurrent pericarditis is a painful inflammatory cardiovascular disease with an estimated United States prevalent population of approximately 40,000 patients seeking and receiving medical treatment. ARCALYST is also approved in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes ("CAPS"), including Familial Cold Autoinflammatory Syndrome ("FCAS") and Muckle-Wells Syndrome in adults and children 12 years and older, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist ("DIRA") in adults and children weighing 10 kg or more.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — | — | — | — | — |
| Cost of revenue | $77.7M | $60.9M | $33.4M | $22.9M | $9.1M | — | — | — | — | — |
| Gross profit | $599.9M | $362.3M | $236.9M | $197.3M | $29.4M | — | — | — | — | — |
| R&D | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M | $112.0M | $135.0M | $86.6M | $56.4M | — |
| SG&A | $196.3M | $168.0M | $129.4M | $98.0M | $85.9M | $45.3M | $35.0M | $21.6M | $9.0M | — |
| Total operating expenses | — | — | — | — | — | $157.4M | $170.0M | $108.2M | $65.4M | — |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M | -$157.4M | -$170.0M | -$108.2M | -$65.4M | — |
| Pre-tax income | $88.9M | -$36.2M | -$16.7M | $11.0M | -$156.5M | -$156.2M | -$163.9M | -$103.4M | -$64.9M | — |
| Income tax | $29.9M | $7.0M | $30.7M | $172.3M | $1.4M | $5.2M | $2.0M | $214.0K | $2.0K | — |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M | -$157.9M | -$161.4M | -$161.9M | -$103.2M | -$64.9M | — |
| EPS, basic | 0.80 | -0.60 | 0.20 | 2.64 | -2.30 | -2.61 | -2.99 | — | — | — |
| EPS, diluted | 0.75 | -0.60 | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 | -3.49 | -35.85 | — |
| Shares, diluted (wtd. avg.) | 79.0M | 71.4M | 71.9M | 70.4M | 68.6M | 61.8M | 54.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $165.6M | $183.6M | $108.0M | $122.7M | $122.5M | $114.2M | $47.1M | $72.2M | $45.7M | $56.1M |
| Short-term investments | $248.5M | $60.0M | $98.4M | $67.9M | $59.7M | $209.4M | $186.5M | $235.3M | $0 | — |
| Receivables | $15.6M | $41.7M | $21.3M | $12.7M | $4.0M | — | — | — | — | — |
| Inventory | $54.9M | $26.4M | $31.1M | $21.6M | $3.7M | — | — | — | — | — |
| Total current assets | $527.2M | $331.8M | $276.3M | $243.1M | $196.4M | $333.2M | $241.6M | $313.8M | $47.1M | — |
| Property, plant and equipment | $1.9M | $662.0K | $734.0K | $1.7M | $2.8M | $4.1M | $6.4M | $6.4M | $125.0K | — |
| Other intangibles | $15.2M | $16.2M | $17.2M | $18.2M | $19.2M | $20.0M | — | — | — | — |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M | $349.5M | $254.5M | $322.0M | $47.5M | — |
| Accounts payable | $2.0M | $2.0M | $8.2M | $7.9M | $1.9M | $503.0K | $5.7M | $10.9M | $1.2M | — |
| Total current liabilities | $139.2M | $100.6M | $63.7M | $47.1M | $44.8M | $31.8M | $27.8M | $42.6M | $17.4M | — |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M | $37.5M | $29.1M | $42.7M | $17.4M | — |
| Retained earnings | -$462.1M | -$521.1M | -$477.9M | -$492.0M | -$675.4M | -$517.5M | -$356.1M | -$194.2M | -$91.0M | — |
| Total equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M | $311.9M | $225.4M | $279.3M | -$89.7M | -$25.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M | -$136.5M | -$158.4M | -$81.0M | -$50.2M | — |
| Depreciation and amortisation | $196.0K | $448.0K | $1.1M | $1.2M | $1.5M | $2.4M | $2.1M | $286.0K | $28.0K | — |
| Stock-based compensation | $37.0M | $30.7M | $27.1M | $25.1M | $25.2M | $20.9M | $15.1M | $5.7M | $897.0K | — |
| Capital expenditure | $1.6M | $277.0K | $130.0K | $105.0K | $415.0K | $283.0K | $3.2M | $5.3M | $69.0K | — |
| Investing cash flow | -$189.0M | $37.7M | -$29.6M | -$8.1M | $128.6M | -$23.4M | $49.2M | -$239.2M | -$69.0K | — |
| Financing cash flow | $33.0M | $12.3M | $1.5M | $2.5M | $5.9M | $227.1M | $84.1M | $346.7M | $39.9M | — |
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-044410.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Gross profit | — | — | — | — | — | $29.4M | $197.3M | $236.9M | $362.3M | $599.9M |
| Net income | — | -$64.9M | -$103.2M | -$161.9M | -$161.4M | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |